Camp4 Therapeutics Files S-1/A Amendment
Ticker: CAMP · Form: S-1/A · Filed: Sep 26, 2024 · CIK: 1736730
Sentiment: neutral
Topics: ipo, sec-filing, biotech
TL;DR
Camp4 Therapeutics filed an S-1/A, moving closer to IPO. Big pharma funding incoming?
AI Summary
Camp4 Therapeutics Corp. filed an S-1/A amendment on September 26, 2024, for its initial public offering. The company, located at One Kendall Square in Cambridge, MA, is a pharmaceutical preparations company (SIC code 2834) incorporated in Delaware. This filing updates their registration statement, indicating progress towards going public.
Why It Matters
This S-1/A filing signifies Camp4 Therapeutics' continued efforts to become a publicly traded company, which could provide significant capital for its drug development programs.
Risk Assessment
Risk Level: medium — As an S-1/A filing, it indicates a company is in the process of going public, which carries inherent market and execution risks for early-stage biotech firms.
Key Numbers
- 333-282241 — SEC File Number (Identifies the specific registration filing with the SEC.)
Key Players & Entities
- Camp4 Therapeutics Corp. (company) — Registrant
- September 26, 2024 (date) — Filing Date
- 333-282241 (registration_number) — SEC File Number
- One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, Massachusetts 02139 (address) — Principal Executive Offices
- Josh Mandel-Brehm (person) — Chief Executive Officer
- 2834 (sic_code) — Pharmaceutical Preparations
FAQ
What is the primary purpose of this S-1/A filing?
This S-1/A filing is an amendment to Camp4 Therapeutics Corp.'s initial registration statement (Form S-1) filed with the SEC, updating information as they prepare for an initial public offering (IPO).
When was this amendment filed with the SEC?
This amendment was filed as of date September 26, 2024.
What is Camp4 Therapeutics Corp.'s principal business address?
The company's principal executive offices are located at One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, Massachusetts 02139.
Who is the Chief Executive Officer of Camp4 Therapeutics Corp.?
Josh Mandel-Brehm is the Chief Executive Officer of Camp4 Therapeutics Corp.
What is Camp4 Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
Camp4 Therapeutics Corp.'s SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 4,506 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-09-26 16:10:59
Filing Documents
- tm2415452-11_s1a.htm (S-1/A) — 3834KB
- tm2415452d12_ex1-1.htm (EX-1.1) — 255KB
- tm2415452d12_ex10-11.htm (EX-10.11) — 86KB
- tm2415452d12_ex23-1.htm (EX-23.1) — 2KB
- lg_camp4-4c.jpg (GRAPHIC) — 22KB
- ph_identify-4c.jpg (GRAPHIC) — 111KB
- fc_ourpipeline-4c.jpg (GRAPHIC) — 53KB
- ph_geneexpression-4c.jpg (GRAPHIC) — 78KB
- bc_functionaldisorder-4c.jpg (GRAPHIC) — 39KB
- ph_sodiumacetate-4c.jpg (GRAPHIC) — 58KB
- pc_ucdpatient-4c.jpg (GRAPHIC) — 50KB
- bc_concentration-4c.jpg (GRAPHIC) — 94KB
- lc_ureaproduction-4clr.jpg (GRAPHIC) — 55KB
- lc_ammonialevel-4c.jpg (GRAPHIC) — 95KB
- lc_ammoniaureagen-4clr.jpg (GRAPHIC) — 52KB
- bc_ucdmrna-4clr.jpg (GRAPHIC) — 51KB
- lc_ureagenesisauc-4c.jpg (GRAPHIC) — 46KB
- fc_clinicaltrialdesign-4c.jpg (GRAPHIC) — 64KB
- lc_syngap1brainsofmice-4clr.jpg (GRAPHIC) — 58KB
- lc_humanneurons-4c.jpg (GRAPHIC) — 55KB
- 0001104659-24-103141.txt ( ) — 5519KB
Risk factors
Risk factors 15 Special Note Regarding Forward-Looking Statements 82 Market and industry data 84
Use of proceeds
Use of proceeds 85 Dividend policy 87 Capitalization 88
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 93
Business
Business 111 Management 157 Executive and director compensation 167 Certain relationships and related party transactions 180 Principal stockholders 184
Description of capital stock
Description of capital stock 187 S hares Eligible for Future Sale 192 Certain Material U.S. Federal Income Tax Consequences to Non U.S. Holders 195
Underwriting
Underwriting 199 Legal matters 211 Experts 211 Where You Can Find More Information 211 Index to consolidated financial statements F-1 Neither we nor the underwriters have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may provide you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information contained in this prospectus is accurate only as of the date on the front cover of this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. TABLE OF CONTENTS P ROSPECTUS SUMMARY This summary highlights, and is qualified in its entirety by, information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before investing in our common stock. You should read this entire prospectus carefully, especially the sections titled "Risk factors," "Business," and "Management's discussion and analys